Analyst Ratings For HTG Molecular Diagnostics (NASDAQ:HTGM)
Today, HC Wainwright reiterated its Buy rating on HTG Molecular Diagnostics (NASDAQ:HTGM) with a price target of $6.00.
Some recent analyst ratings include
- 2/1/2018-HC Wainwright Reiterated Rating of Buy.
- 3/28/2016-Leerink Swann Reiterated Rating of Outperform.
Recent Insider Trading Activity For HTG Molecular Diagnostics (NASDAQ:HTGM)
HTG Molecular Diagnostics (NASDAQ:HTGM) has insider ownership of 7.60% and institutional ownership of 13.60%.
- On 12/1/2017 Shaun D Mcmeans, VP, sold 945 with an average share price of $2.11 per share and the total transaction amounting to $1,993.95.
- On 11/1/2017 Shaun D Mcmeans, CFO, sold 945 with an average share price of $2.26 per share and the total transaction amounting to $2,135.70.
- On 10/16/2017 Shaun D Mcmeans, VP, sold 946 with an average share price of $2.27 per share and the total transaction amounting to $2,147.42.
- On 8/25/2017 Holdings A/S Novo, Major Shareholder, sold 1,149,813 with an average share price of $1.81 per share and the total transaction amounting to $2,081,161.53.
- On 8/24/2017 Holdings A/S Novo, Major Shareholder, sold 382,437 with an average share price of $1.91 per share and the total transaction amounting to $730,454.67.
- On 8/23/2017 Holdings A/S Novo, Major Shareholder, sold 47,162 with an average share price of $2.02 per share and the total transaction amounting to $95,267.24.
- On 8/22/2017 Holdings A/S Novo, Major Shareholder, sold 80,586 with an average share price of $2.07 per share and the total transaction amounting to $166,813.02.
Recent Trading Activity for HTG Molecular Diagnostics (NASDAQ:HTGM)
Shares of HTG Molecular Diagnostics closed the previous trading session at 3.58 up +0.01 0.28% with 3.549999952316284 shares trading hands.